Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Pharma Spends $570 Million for Two Acquisitions

publication date: Dec 15, 2010
Shanghai Pharmaceuticals Holding Co. plans to spend 3.8 billion RMB ($570 million) to buy two China drug distribution-manufacturing companies. In one deal, Shanghai Pharma will pay 1.5 billion RMB ($225 million) for the antibiotics business of its parent company, Shanghai Pharmaceutical Group. And it finalized the terms on a previously announced transaction, acquiring 65% of China Health System (CHS) for 2.3 billion RMB ($345 million). More details....

Stock Symbol: (SHEX: 601607)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital